Tranexamic Acid in Dacryocystorhinostomy (TA-DCR)
|ClinicalTrials.gov Identifier: NCT01221909|
Recruitment Status : Unknown
Verified October 2010 by HaEmek Medical Center, Israel.
Recruitment status was: Not yet recruiting
First Posted : October 15, 2010
Last Update Posted : October 15, 2010
Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective, double blind, placebo controlled study.
The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in DCR surgery, and might reduce the duration of the surgery.
|Condition or disease||Intervention/treatment||Phase|
|Nasolacrimal Tract Obstruction||Drug: Tranexamic acid Drug: saline solution||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Single Dose Tranexamic Acid for Dacryocystorhinostomy|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
|Experimental: Tranexamic acid single dose of 500mg||
Drug: Tranexamic acid
Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
|Placebo Comparator: Saline||
Drug: saline solution
5cc saline solution
- Duration of DCR surgery in minutes and amount of blood loss in milliliters during surgery. [ Time Frame: Blood loss will be measured at the end of DCR operation from the suction bowel. Duration of surgery will be caculated by registering time of operation start and end. ]
- Late onset postoperative epistaxis or periorbital hematoma [ Time Frame: 8 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01221909
|Contact: Haneen Jabaly-Habib, M.D.||firstname.lastname@example.org|
|Contact: Abed Mukari, M.D.||email@example.com|
|Dept. of Ophthalmology, HaEmek medical center||Not yet recruiting|
|Afula, Israel, 18101|
|Contact: Haneen Jabaly-Habib, M.D. 972-506268059 firstname.lastname@example.org|
|Contact: Abed Mukari, M.D. 972-546881532 email@example.com|
|Sub-Investigator: Haneen Jabaly-Habib, M.D.|
|Sub-Investigator: Abed Mukari, M.D.|
|Principal Investigator: Daniel Briscoe, M.D.|